Skip to content
stoqly
en

Languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Kazia Therapeutics Ltd

KZIA Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Kazia Therapeutics Ltd had $0.0M of revenue in fiscal 2025, down 98.2% on the year before.

Download report 3-page PDF: the company, its results and charts with peers.

What Kazia Therapeutics Ltd does

KZIA Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
KAZIA THERAPEUTICS LTD
Fiscal year ends
June 30, 2025
Latest annual report
20-F Β· Nov 7, 2025
Accession Β· CIK
0001193125-25-272284 Β· 0001075880

KIRA’s summary AI analyst

Hi! I read Kazia Therapeutics Ltd’s latest annual report (fiscal 2025). Here is what stands out:

1 strength 3 to watch

Kazia Therapeutics Ltd in 30 seconds

Good So-so Weak

Weak

Are sales growing?

βˆ’98.2%

No. Sales fell 98.2% last year.

Weak

Does it make a profit?

βˆ’49,261.0%

No. It lost money last year.

Weak

How healthy are the accounts?

2 / 8

Weak. It passes 2 of 8 health tests.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
β€”
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”

Revenue

Total sales reported in the income statement.

KIRA Β· Kazia Therapeutics Ltd had $0.0M of revenue in fiscal 2025, down 98.2% on the year before.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Kazia Therapeutics Ltd lost $13.4M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’

Sales and profit

Is it selling more, and how much does it keep?

Results dates

In plain words: Every quarter, companies publish how much they sold and earned. These are the days Kazia Therapeutics Ltd did it, and the next one. Share prices often move a lot on those days.

Next results

November 6, 2026

Friday Β· in 11 days

Time
After the market closes
Covers
Period ended Jun 30, 2026
Source
Stoqly estimate

Estimated from the same quarter last year. It will be replaced by the announced date once there is one.

See who else reports that week β†’
Date Results for Time Source
Nov 7, 2025 Period ended Jun 30, 2025 After the market closes 20-F β†—
Nov 15, 2024 Period ended Jun 30, 2024 After the market closes 20-F β†—
Oct 26, 2023 Period ended Jun 30, 2023 Before the market opens 20-F β†—
Oct 17, 2022 Period ended Jun 30, 2022 Before the market opens 20-F β†—
Oct 7, 2021 Period ended Jun 30, 2021 Before the market opens 20-F β†—
Oct 22, 2020 Period ended Jun 30, 2020 Before the market opens 20-F β†—
Oct 21, 2019 Period ended Jun 30, 2019 Before the market opens 20-F β†—
Oct 24, 2018 Period ended Jun 30, 2018 Before the market opens 20-F β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

Revenue and margins

KIRA Β· Kazia Therapeutics Ltd had $0.0M of revenue in fiscal 2025, down 98.2% on the year before.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Kazia Therapeutics Ltd lost $13.4M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

KIRA Β· Kazia Therapeutics Ltd returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 107.8%.

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· No open-market insider trades in the last 12 months.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA Β· Kazia Therapeutics Ltd has $2.6M more cash than debt.

Cash, debt and the ratios that show how comfortably Kazia Therapeutics Ltd can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $20.7M$5.1M$3.5M$1.1M$2.8M
Debt incl. finance leases $0.0M$1.3M$1.2M$0.4M$0.3M
Debt / equity 0.0x0.1x0.1xβ€”β€”
Current ratio 3.5x1.4x1.4x0.2x0.4x
Quick ratio 3.5x1.4x1.4x0.2x0.4x
Total assets $43.5M$24.7M$18.6M$14.4M$4.0M
Total liabilities $15.2M$12.1M$10.6M$21.0M$9.4M
Shareholders' equity $28.4M$12.6M$8.0Mβˆ’$6.7Mβˆ’$5.4M
Net debt (βˆ’ = net cash) βˆ’$20.7Mβˆ’$3.8Mβˆ’$2.3Mβˆ’$0.7Mβˆ’$2.6M

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Kazia Therapeutics Ltd passes 2 of 8 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” β€” βœ“ βœ• βœ• βœ“ βœ• βœ• βœ• βœ•
Cash from operations exceeds net income βœ“ βœ• βœ• βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€” βœ• βœ• βœ“ βœ•
Current ratio rose β€” β€” βœ• βœ“ βœ• βœ“ βœ• βœ“ βœ• βœ“
Share count didn't rise β€” βœ• βœ“ βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” βœ• β€” β€” β€” βœ• βœ• βœ“ βœ•
F-score β€” / 3β€” / 42 / 7β€” / 6β€” / 6β€” / 61 / 82 / 83 / 82 / 8
Accruals ratio β€”2.1%8.4%βˆ’14.3%βˆ’16.0%1.7%βˆ’4.8%βˆ’16.5%βˆ’68.4%βˆ’52.4%
Altman Z'' β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $0.3M $0.2M $0.1M β€” β€” $11.3M $0.0M $0.0M $1.5M $0.0M
Research and development $7.2M $8.4M $7.6M $4.6M $6.4M $10.8M $14.6M $10.5M $11.4M $4.7M
Interest expense $0.0M $0.0M $0.0M β€” β€” β€” β€” β€” β€” β€”
Pretax income βˆ’$8.8M βˆ’$8.2M βˆ’$4.9M βˆ’$7.6M βˆ’$8.6M βˆ’$6.6M βˆ’$18.4M βˆ’$13.9M βˆ’$17.7M βˆ’$14.5M
Income tax β€” βˆ’$0.2M βˆ’$0.2M βˆ’$0.2M βˆ’$0.2M βˆ’$0.4M βˆ’$0.3M βˆ’$0.2M βˆ’$0.2M βˆ’$1.1M
Net income βˆ’$8.8M βˆ’$8.0M βˆ’$4.7M βˆ’$7.3M βˆ’$8.4M βˆ’$6.3M βˆ’$18.1M βˆ’$13.8M βˆ’$17.6M βˆ’$13.4M
Net income to common βˆ’$8.8M βˆ’$8.0M βˆ’$4.7M βˆ’$7.3M βˆ’$8.4M βˆ’$6.3M βˆ’$18.1M βˆ’$13.8M βˆ’$17.6M βˆ’$13.4M
Diluted EPS βˆ’$2.05 βˆ’$1.72 βˆ’$9.67 βˆ’$12.77 βˆ’$0.11 βˆ’$0.05 βˆ’$0.14 βˆ’$0.08 βˆ’$0.07 βˆ’$0.02
Diluted shares 0.43B 0.47B 0.05B 0.06B 0.07B 0.12B 0.13B 0.18B 0.26B 0.55B
Cash flow
Cash from operations βˆ’$8.7M βˆ’$8.6M βˆ’$6.7M βˆ’$4.8M βˆ’$5.9M βˆ’$6.8M βˆ’$16.5M βˆ’$10.2M βˆ’$6.3M βˆ’$8.6M
Capital expenditure $0.4M $0.0M β€” β€” β€” β€” β€” β€” β€” β€”
Free cash flow βˆ’$9.1M βˆ’$8.6M β€” β€” β€” β€” β€” β€” β€” β€”
Depreciation and amortization $0.5M $1.1M $1.2M $0.8M $0.7M $0.9M $1.4M $1.3M β€” β€”
Stock-based compensation $0.3M $0.4M $0.1M $0.2M $0.2M $0.5M $1.2M $0.8M $0.3M $0.4M
Acquisitions β€” $5.4M β€” β€” β€” β€” β€” β€” β€” β€”
Dividends paid β€” $0.0M $0.0M $0.0M β€” β€” β€” $0.0M $0.0M $0.0M
Dividends and buybacks β€” $0.0M $0.0M $0.0M β€” β€” β€” $0.0M $0.0M $0.0M
Balance sheet
Cash and short-term investments $24.9M $11.1M $4.4M $3.8M $6.0M $20.7M $5.1M $3.5M $1.1M $2.8M
Total debt β€” β€” β€” β€” β€” $0.0M $1.3M $1.2M $0.4M $0.3M
Current assets β€” $15.0M $6.8M $5.3M $7.3M $22.0M $6.5M $7.1M $4.1M $3.2M
Current liabilities β€” $4.1M $2.9M $1.3M $3.5M $6.2M $4.6M $5.0M $17.2M $9.2M
Property and equipment, net $0.4M $0.4M $0.0M β€” β€” β€” β€” β€” β€” β€”
Intangible assets $0.6M $12.2M $10.8M $9.5M $8.5M $15.7M $13.2M $11.4M $10.3M $0.7M
Total assets β€” $27.6M $20.8M $14.8M $15.8M $43.5M $24.7M $18.6M $14.4M $4.0M
Total liabilities β€” $8.1M $6.6M $4.9M $6.1M $15.2M $12.1M $10.6M $21.0M $9.4M
Shareholders' equity $25.2M $19.5M $14.2M $9.9M $9.7M $28.4M $12.6M $8.0M βˆ’$6.7M βˆ’$5.4M
Margins
Net margin βˆ’2,971.3% βˆ’4,286.0% βˆ’5,075.3% β€” β€” βˆ’55.5% β€” β€” βˆ’1,160.2% βˆ’49,261.0%
FCF margin βˆ’3,079.5% βˆ’4,598.1% β€” β€” β€” β€” β€” β€” β€” β€”
Returns
Return on equity βˆ’34.8% βˆ’36.0% βˆ’27.8% βˆ’60.8% βˆ’85.1% βˆ’33.0% βˆ’88.6% βˆ’133.9% βˆ’2,668.2% β€”
Return on assets β€” βˆ’29.2% βˆ’19.3% βˆ’41.2% βˆ’54.5% βˆ’21.2% βˆ’53.2% βˆ’63.6% βˆ’106.4% βˆ’146.2%
Return on tangible equity βˆ’35.6% βˆ’111.1% βˆ’135.9% βˆ’1,495.4% βˆ’710.9% βˆ’49.8% β€” β€” β€” β€”
Growth
Revenue growth β€” βˆ’36.5% βˆ’50.9% β€” β€” β€” βˆ’100.0% β€” β€” βˆ’98.2%
Share count change β€” 9.5% βˆ’89.7% 18.9% 27.0% 61.1% 12.6% 39.1% 43.1% 107.8%
Financial health
Debt / equity β€” β€” β€” β€” β€” 0.0x 0.1x 0.1x β€” β€”
Current ratio β€” 3.6x 2.4x 4.0x 2.1x 3.5x 1.4x 1.4x 0.2x 0.4x
Quick ratio β€” 3.6x 2.4x 4.0x 2.1x 3.5x 1.4x 1.4x 0.2x 0.4x
Capital allocation
Capex / revenue 128.6% 4.8% β€” β€” β€” β€” β€” β€” β€” β€”
Stock comp / revenue 91.6% 207.7% 138.7% β€” β€” 4.2% β€” β€” 23.1% 1,553.7%
Quality scores
Piotroski F-score β€” β€” 2.0 β€” β€” β€” 1.0 2.0 3.0 2.0
Accruals ratio β€” 2.1% 8.4% βˆ’14.3% βˆ’16.0% 1.7% βˆ’4.8% βˆ’16.5% βˆ’68.4% βˆ’52.4%

Source: SEC EDGAR XBRL filings (CIK 0001075880). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in AUD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. The ADS ratio could not be read from the filing, so market cap and valuation are not shown. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open